Portable Device Finds Sepsis Infection Markers
By LabMedica International staff writers Posted on 20 Jul 2017 |
Image: University of Illinois researchers and physicians at Carle Foundation Hospital developed a rapid test for sepsis that counts white blood cells and certain protein markers on their surface to monitor a patient\'s immune response (Photo courtesy of Janet Sinn-Hanlon).
A new portable device can quickly find markers of deadly, unpredictable sepsis infection from a single drop of blood, which is the first to provide rapid, point-of-care measurement of the immune system's response, without any need to process the blood.
Sepsis is routinely detected by monitoring patients' vital signs, such as blood pressure, oxygen levels, temperature and others. If a patient shows signs of being septic, the doctors try to identify the source of the infection with blood cultures and other tests that can take days, time the patient may not have. The new device takes a different approach.
Scientists at the University of Illinois at Urbana-Champaign (Urbana, IL, USA) and their colleagues tested the device with blood samples from patients in the intensive care unit (ICU) and emergency room. When a physician suspected infection and ordered a blood test, a small drop of the blood drawn was given to the team, stripped of identifying information to preserve patient confidentiality. The team was able to monitor CD64 levels over time, correlating them with the patient's vital signs. They found that the results from the rapid test correlated well with the results from the traditional tests and with the patients' vital signs. The small, lab-on-a-chip device counts white blood cells in total as well as specific white blood cells called neutrophils, and measures a protein marker called CD64 on the surface of neutrophils. The levels of CD64 surge as the patient's immune response increases.
Rashid Bashir, PhD, a professor of bioengineering and lead investigator, said, “We are looking at the immune response, rather than focusing on identifying the source of the infection. One person's immune system might respond differently from somebody else's to the same infection. In some cases, the immune system will respond before the infection is detectable. This test can complement bacterial detection and identification. We think we need both approaches: detect the pathogen, but also monitor the immune response.”
The team is working to incorporate measurements for other inflammation markers into the rapid-testing device to give a more complete picture of the body's response, and to enable earlier detection. They also have a startup company, Prenosis Inc (Champaign, IL, USA) that is working to commercialize the device. The study was published on July 3, 2017, in the journal Nature Communications.
Related Links:
University of Illinois at Urbana-Champaign
Prenosis
Sepsis is routinely detected by monitoring patients' vital signs, such as blood pressure, oxygen levels, temperature and others. If a patient shows signs of being septic, the doctors try to identify the source of the infection with blood cultures and other tests that can take days, time the patient may not have. The new device takes a different approach.
Scientists at the University of Illinois at Urbana-Champaign (Urbana, IL, USA) and their colleagues tested the device with blood samples from patients in the intensive care unit (ICU) and emergency room. When a physician suspected infection and ordered a blood test, a small drop of the blood drawn was given to the team, stripped of identifying information to preserve patient confidentiality. The team was able to monitor CD64 levels over time, correlating them with the patient's vital signs. They found that the results from the rapid test correlated well with the results from the traditional tests and with the patients' vital signs. The small, lab-on-a-chip device counts white blood cells in total as well as specific white blood cells called neutrophils, and measures a protein marker called CD64 on the surface of neutrophils. The levels of CD64 surge as the patient's immune response increases.
Rashid Bashir, PhD, a professor of bioengineering and lead investigator, said, “We are looking at the immune response, rather than focusing on identifying the source of the infection. One person's immune system might respond differently from somebody else's to the same infection. In some cases, the immune system will respond before the infection is detectable. This test can complement bacterial detection and identification. We think we need both approaches: detect the pathogen, but also monitor the immune response.”
The team is working to incorporate measurements for other inflammation markers into the rapid-testing device to give a more complete picture of the body's response, and to enable earlier detection. They also have a startup company, Prenosis Inc (Champaign, IL, USA) that is working to commercialize the device. The study was published on July 3, 2017, in the journal Nature Communications.
Related Links:
University of Illinois at Urbana-Champaign
Prenosis
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms